title: Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
authors.forename: M K
authors.initials: MK
authors.lastname: Andersen
authors.forename: J
authors.initials: J
authors.lastname: Pedersen-Bjergaard
authors.forename: L
authors.initials: L
authors.lastname: Kjeldsen
authors.forename: I H
authors.initials: IH
authors.lastname: Dufva
authors.forename: K
authors.initials: K
authors.lastname: Brøndum-Nielsen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002898:Chromosomes, Human, Pair 8; D006410:Hematopoiesis / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D014314:Trisomy
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate